Bausch + Lomb, the global ophthalmological giant, has officially announced a strategic shift in its clinical pipeline. The company is discontinuing the development of its experimental glaucoma treatment, BL1107, after the drug failed to meet primary endpoints in a mid-stage clinical trial. However, the move is not a total abandonment of the asset; instead, the company is reallocating resources to test the drug for the treatment of geographic atrophy (GA), an advanced and debilitating form of age-related macular degeneration.
This decision underscores the high-stakes nature of ophthalmic drug development, where early promise often meets the harsh reality of clinical trial data. While the failure in the glaucoma space is a setback for the company’s immediate pipeline, Bausch + Lomb’s pivot suggests a long-term commitment to the asset, fueled by a collaboration with Ripple Therapeutics to leverage innovative sustained-release delivery technology.
The Core Facts: A Trial Missed, A New Path Forged
The news of the clinical trial results, released after the market close on Thursday, signaled that the topical administration of BL1107 failed to replicate the visual function improvements observed in earlier, smaller-scale studies. The Phase 2 study, which utilized a 28-day regimen of the experimental eye drop, failed to hit its primary efficacy goal. Furthermore, the drug fell short of secondary trial goals related to broader measures of visual function.
Despite these failures, the data provided a silver lining. The drug successfully engaged its target, evidenced by a reduction in intraocular eye pressure—a key indicator of clinical activity. Importantly, the safety profile remained consistent with historical data, with no new safety signals emerging. This favorable safety profile is a critical prerequisite for the company’s transition to its next target: geographic atrophy.
BL1107 is a small molecule agonist of the alpha-2 receptor. This receptor is located in both the central and peripheral nervous systems and is a well-validated target in the ophthalmology sector, currently addressed by several FDA-approved therapies that reduce intraocular pressure to manage glaucoma. By shifting focus, Bausch + Lomb intends to leverage the drug’s mechanism of action to address the complex pathology of GA, rather than the pressure-related mechanics of glaucoma.
Chronology of Development: From Acquisition to Realignment
The journey of BL1107, formerly known as WB007, is deeply tied to Bausch + Lomb’s aggressive expansion of its R&D portfolio.
- 2025 – The Acquisition: Bausch + Lomb acquired Whitecap Biosciences in a deal designed to bolster its clinical pipeline. While specific financial terms were initially kept private, subsequent regulatory filings revealed a $28 million upfront payment, alongside commitments for milestone payments and royalties on future commercialized products.
- Early Development: At the time of the Whitecap deal, BL1107 was already being explored for both glaucoma and geographic atrophy. The company prioritized the glaucoma program based on encouraging results from Phase 1/2a studies.
- 2026 – The Glaucoma Setback: Following the completion of the Phase 2 clinical trial for glaucoma, the data revealed a lack of efficacy regarding visual function. The decision to discontinue this specific indication was formalized immediately following the data analysis.
- 2028 – The Outlook: Looking ahead, Bausch + Lomb has announced that its clinical trials for BL1107 in patients with geographic atrophy are scheduled to commence in 2028.
The Landscape of Geographic Atrophy: A Competitive Battlefield
Geographic atrophy (GA) represents a major unmet need in retinal health. As an advanced form of dry age-related macular degeneration, it involves the progressive deterioration of the macula, leading to a permanent loss of central vision.
Currently, the FDA-approved landscape is dominated by two primary therapies:
- Syfovre: Originally developed by Apellis Pharmaceuticals, this therapy is now under the umbrella of Biogen following a massive $5.6 billion acquisition earlier in 2026.
- Izervay: Developed by Iveric Bio, this drug is now part of the Astellas Pharma portfolio.
Both drugs represent significant scientific breakthroughs, functioning by inhibiting specific proteins in the complement system, which are associated with the chronic inflammation that drives retinal damage in GA patients. However, both Syfovre and Izervay share a common drawback: they require frequent, direct injections into the eye. This creates a significant treatment burden for patients, many of whom are elderly and may struggle with the logistics of frequent clinical visits for intravitreal injections.
Bausch + Lomb’s strategy to differentiate BL1107 lies in its delivery method. The company is partnering with Ripple Therapeutics, a firm that utilizes a proprietary platform capable of engineering drugs into controlled-release formulations without the use of synthetic polymers. By utilizing a sustained-release implant, Bausch + Lomb hopes to offer a "set it and forget it" alternative to the frequent injections required by its competitors.
Historical Context: Learning from Past Failures
The path to developing an alpha-2 agonist for geographic atrophy via an implant is not without precedent—or without risk. Allergan previously explored this exact avenue with brimonidine, a staple drug in the glaucoma field since the 1990s.
Allergan’s program reached Phase 2b testing, utilizing a biodegradable intravitreal implant to deliver the drug directly to the site of the disease. However, the program was terminated after the company failed to observe a statistically significant difference in GA progression between the treatment group and the control group, largely due to a lower-than-expected rate of progression in the sham-treated patients.
Bausch + Lomb is undoubtedly analyzing these historical data points to refine their own clinical trial design for the 2028 launch. The challenge in GA trials is often the selection of patient populations and the length of time required to see meaningful structural changes in the retina.
Official Responses and Strategic Implications
For Bausch + Lomb, the decision to drop the glaucoma indication is viewed not as a defeat, but as a calculated refinement of their R&D strategy. The company currently manages a massive portfolio of over 60 assets at various stages of development.
Yehia Hashad, executive vice president of R&D and chief medical officer at Bausch + Lomb, addressed the pivot in a prepared statement. "We’ve intentionally built a diversified pipeline because we know innovation requires pursuing multiple scientific hypotheses simultaneously," Hashad noted. "Not every program will succeed, but every study helps us make smarter decisions about where to invest."
Implications for Investors and Stakeholders
- Portfolio Diversification: The shift highlights the importance of the company’s broader R&D strategy. By not pinning the company’s success on a single asset or a single indication, Bausch + Lomb mitigates the risk associated with clinical trial failures.
- Operational Efficiency: The decision to cease the glaucoma program allows the company to focus its capital and human resources on the GA indication, where the potential for market disruption—via the sustained-release delivery mechanism—is significantly higher.
- The Power of Delivery Systems: The partnership with Ripple Therapeutics indicates a broader industry trend toward "drug-device" combinations. As the pharmaceutical industry hits a plateau in identifying new small-molecule targets, innovation in how these drugs are delivered is becoming the primary driver of value.
Conclusion
The transition of BL1107 from a failed glaucoma candidate to a potential GA treatment is a microcosm of modern pharmaceutical development. It is a sector where the line between success and failure is often drawn by the nuances of trial design and the efficacy of delivery mechanisms. While Bausch + Lomb faces the immediate challenge of explaining a clinical miss to its investors, the pivot to a sustained-release GA treatment suggests that the company is playing a longer game.
With the 2028 trial start date looming, the ophthalmological community will be watching closely to see if Bausch + Lomb can succeed where others have struggled, potentially providing patients with a much-needed, less burdensome alternative to current standards of care. For now, the company remains firm in its belief that its diversified portfolio remains the most robust defense against the inherent uncertainties of medical research.
